PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

🧠 Clinical library

Clinical Specialty Index

623 articles indexed across 24 specialties, each reviewed by a licensed pharmacist before publication.

Showing 90 from 1 topic.Sort: Newest | Oldest
Comparative Safety Signals for Melanoma Checkpoint Inhibitors Across Trials and FAERS
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low

Immune checkpoint inhibitors in melanoma: safety profiles unveiled.

Oral Aprepitant Versus IV Fosaprepitant: Comparable CINV Control in Practice
Analysis Oncology Pharmacy Confirmatory Grade: Low

Aprepitant and fosaprepitant are equally effective in real-world chemotherapy settings.

Bevacizumab Adds Survival in Elderly Driver-Negative Lung Adenocarcinoma
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low
Also in Geriatrics

Bevacizumab boosts survival in elderly lung cancer patients.

IO Plus TKI Shows No Survival Gain in Favourable-Risk RCC
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low

Combination therapy may not benefit favourable-risk metastatic renal cell carcinoma patients.

Venetoclax TDM Reduces Toxicity Risk in Posaconazole-Treated AML Patients
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low
Also in Pharmacokinetics / TDM

Venetoclax levels spike with posaconazole: TDM is essential.

Daraxonrasib Halves Death Risk in Previously Treated Pancreatic Cancer
Analysis Oncology Pharmacy Practice-changing Grade: Moderate

Daraxonrasib doubles survival in metastatic pancreatic cancer.

Neoadjuvant Chemotherapy Enables Pregnancy Continuation in Cervical Cancer
Analysis Oncology Pharmacy Hypothesis-generating Grade: Very Low
Also in Women's Health / Reproductive

Innovative cervical cancer treatment preserves pregnancy in cancer patients.

Immunotherapy May Enable Safe Axillary De-escalation in Node-Positive TNBC
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low

Chemo-immunotherapy may enable less invasive breast cancer surgeries.

Two-Year Lenalidomide Maintenance Matches Indefinite Therapy in Standard-Risk Myeloma
Analysis Oncology Pharmacy Practice-changing Grade: Moderate

Two-year lenalidomide is as effective as indefinite therapy in multiple myeloma.

CNS Hemorrhage Signal With MAPK-Pathway Inhibitors Demands Risk Stratification
Analysis Neurology / Neuropharmacology Hypothesis-generating Grade: Low
Also in Oncology

MAPK-pathway inhibitors pose a serious intracranial hemorrhage risk in neuro-oncology.

Navigating Three BCMA-Targeted Modalities and Their Optimal Sequencing in Myeloma
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low

BCMA-targeted therapies revolutionize multiple myeloma care, balancing efficacy with unique toxicities.

Adjuvant TACE and Lenvatinib-Tislelizumab Show Comparable Post-Resection Benefit
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low

Adjuvant therapies improve survival in high-risk liver cancer patients.

Transporters and CYP3A4 Shape Daraxonrasib Brain and Plasma Exposure
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low
Also in Pharmacokinetics / TDM

Transporter interactions may challenge daraxonrasib's effectiveness against brain metastases.

Immune Checkpoint Inhibitors Redefine First-Line Cholangiocarcinoma Therapy
Analysis Oncology Pharmacy Confirmatory Grade: Moderate

Immune checkpoint inhibitors redefine advanced cholangiocarcinoma treatment.

Targeted Therapy Evolution: From Kinase Inhibitors to Protein Degraders
Analysis Oncology Pharmacy Hypothesis-generating Grade: Very Low

Targeted cancer therapies revolutionize personalized oncology treatment.